Literature DB >> 8848143

Nerve growth factor withdrawal induces the apoptotic death of developing septal cholinergic neurons in vitro: protection by cyclic AMP analogue and high potassium.

J N Kew1, D W Smith, M V Sofroniew.   

Abstract

Nerve growth factor regulates the developmental programmed cell death of certain neurons in the peripheral nervous system. The functions of nerve growth factor in the central nervous system are less well characterized. Nerve growth factor withdrawal results in the protein synthesis-dependent death of a large percentage of developing septal cholinergic neurons in sandwich tissue culture. In this study double labelling techniques were used to demonstrate that septal cholinergic neurons subjected to nerve growth factor withdrawal exhibit condensed chromatin and fragmented nuclei, and are labelled intensely for fragmented DNA. These degenerative changes are characteristic of apoptotic cell death. Half of the cholinergic neurons were committed to die and could no longer be rescued by nerve growth factor reapplication following approximately 16.5 h of nerve growth factor deprivation, whereas half of the cholinergic neurons could no longer be rescued by cycloheximide addition after only 9 h of nerve growth factor deprivation, suggesting that nerve growth factor and cycloheximide effect rescue by distinct mechanisms. Addition of a cyclic AMP analogue or depolarization with high K+, but not the general nuclease inhibitor aurintricarboxylic acid, prevented the death of cultured septal cholinergic neurons subjected to nerve growth factor withdrawal. Furthermore, these agents are capable of rescuing cholinergic neurons subjected to a period of nerve growth factor withdrawal after which addition of cycloheximide is no longer protective. Thus, nerve growth factor, cyclic AMP and high K+ can effect rescue after inhibition of translation ceases to be protective. These findings suggest that under defined conditions in vitro, withdrawal of nerve growth factor from septal cholinergic neurons during a critical period of development results in the apoptotic death of these CNS neurons, which can be prevented at the post-translational level by nerve growth factor, cyclic AMP and high K+.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8848143     DOI: 10.1016/0306-4522(95)00365-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta.

Authors:  M Li; X Wang; M K Meintzer; T Laessig; M J Birnbaum; K A Heidenreich
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Swedish Nerve Growth Factor Mutation (NGFR100W) Defines a Role for TrkA and p75NTR in Nociception.

Authors:  Kijung Sung; Luiz F Ferrari; Wanlin Yang; ChiHye Chung; Xiaobei Zhao; Yingli Gu; Suzhen Lin; Kai Zhang; Bianxiao Cui; Matthew L Pearn; Michael T Maloney; William C Mobley; Jon D Levine; Chengbiao Wu
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

3.  Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway.

Authors:  M Villalba; J Bockaert; L Journot
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

4.  The pro-apoptotic substance thapsigargin selectively stimulates re-growth of brain capillaries.

Authors:  Celine Ullrich; Christian Humpel
Journal:  Curr Neurovasc Res       Date:  2009-08-01       Impact factor: 1.990

5.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.

Authors:  Yazhou Li; TracyAnn Perry; Mark S Kindy; Brandon K Harvey; David Tweedie; Harold W Holloway; Kathleen Powers; Hui Shen; Josephine M Egan; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri; Mark P Mattson; Barry J Hoffer; Yun Wang; Nigel H Greig
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.